Analysts delivered mixed verdicts on Eli Lilly after the drugmaker released late-stage trial results for its investigational oral weight-loss drug Orforglipron, sending shares sharply lower on ...
Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback